A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
This randomized phase II trial studies how well veliparib together with gemcitabine
hydrochloride and cisplatin works compared to gemcitabine hydrochloride and cisplatin alone
in treating patients with pancreatic cancer that has spread from where it started to nearby
tissue or lymph nodes (locally advanced) or spread from the primary site (place where it
started) to other places in the body (metastatic). Veliparib may stop the growth of tumour
cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy,
such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth
of tumour cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. It is not yet known whether giving veliparib together with gemcitabine
hydrochloride and cisplatin is an effective treatment for pancreatic cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society